产品
编 号：F747884
分子式：C20H23N5O
分子量：349.43
分子式：C20H23N5O
分子量：349.43
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1919828-81-1
产品详情
生物活性：
DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance.
体内研究：
DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg.DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values.Animal Model:Wistar rats
Dosage:Tail vein injection
Administration:20 mg/kg
Result:Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.
Animal Model:Rats
Dosage:I.v. bolus injection (Pharmacokinetic Analysis)
Administration:10 mg/kg; 0~25 hours
Result:Rapidly eliminated the half-life elimination and the plasmatic clearance values.
体外研究：
DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase.
DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance.
体内研究：
DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg.DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values.Animal Model:Wistar rats
Dosage:Tail vein injection
Administration:20 mg/kg
Result:Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.
Animal Model:Rats
Dosage:I.v. bolus injection (Pharmacokinetic Analysis)
Administration:10 mg/kg; 0~25 hours
Result:Rapidly eliminated the half-life elimination and the plasmatic clearance values.
体外研究：
DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备